Sign in
VYGR Stock Price, Chart, Stats & News
Voyager Therapeutics, Inc.
Save
211.47M
Market cap
–
Current P/E
8.44x
Forward P/E
VYGR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -326.56% |
Pretax margin | -296.17% |
Net margin | -296.53% |
Effective tax rate | -0.12% |
ROA | -47.46% |
ROE | -51.35% |
D/E | 0.19x |
Interest coverage ratio | – |
VYGR valuation
P/E | – |
P/S | 5.85x |
P/B | 1.19x |
P/CF | -1.75x |
P/FCF | -1.75x |
P/OCF | -1.75x |
PEG | -0.35x |
EV multiple | -2.12x |
About
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia.
Similar securities
Based on sector and market capitalization
Report issue